Recent advancements in the exploitation of the gut microbiome in the diagnosis and treatment of colorectal cancer. Issue 7 (30th July 2021)

• Record Type: Journal Article
• Authors: Stott, Katie J.; Phillips, Bethan; Parry, Lee; May, Stephanie
• Is Part Of: Bioscience reports. Volume 41:Issue 7(2021)
• Publication Date: 2021-07-30
• Subjects: bacterio-thearpy -- colorectal cancer -- diagnostic biomarkers -- intestine -- microbiome; Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20204113
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract: Over the last few decades it has been established that the complex interaction between the host and the multitude of organisms that compose the intestinal microbiota plays an important role in human metabolic health and disease. Whilst there is no defined consensus on the composition of a healthy microbiome due to confounding factors such as ethnicity, geographical locations, age and sex, there are undoubtably populations of microbes that are consistently dysregulated in gut diseases including colorectal cancer (CRC). In this review, we discuss the most recent advances in the application of the gut microbiota, not just bacteria, and derived microbial compounds in the diagnosis of CRC and the potential to exploit microbes as novel agents in the management and treatment of CRC. We highlight examples of the microbiota, and their derivatives, that have the potential to become standalone diagnostic tools or be used in combination with current screening techniques to improve sensitivity and specificity for earlier CRC diagnoses and provide a perspective on their potential as biotherapeutics with translatability to clinical trials.